Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRF7 inhibitor
- Development stage
- Preclinical
- Lead developer
- Hamlet Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
The IRF7 inhibitor is an siRNA-based drug candidate developed by Hamlet BioPharma (following its merger with SelectImmune Pharma) for the treatment of severe bacterial infections, including kidney infections and urosepsis. The drug utilizes small interfering RNA (siRNA) to knockdown the expression of Interferon Regulatory Factor 7 (IRF7), a transcription factor that plays a critical role in the destructive innate immune response triggered during severe infections. By inhibiting IRF7, the treatment aims to modulate the immune system and prevent the life-threatening inflammatory damage associated with sepsis. The program has demonstrated positive data in animal models and is currently in the preclinical development stage, with the company intending to advance it toward clinical studies for conditions such as urosepsis.
- Other names
- IRF7-siRNAIRF-7-siRNAIRF 7-siRNA
02
Targets
IRF7 (Interferon regulatory factor 7)
Beyond the preview
Go deeper on IRF7 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRF7 inhibitor.